I guess my view is by 2032 Zilosul will have achieved its blockbuster status and PAR will reach big pharma status. I just can't see any of the current management team being capable of running a big pharma company and there could be pressure for PAR to relocate to a new destination to help facilitate this. USA was a lazy suggestion on my part, while Germany and Switzerland could be alternatives.
Now we just need to see the 6 month readout for 008 and readout for stage 1 002. Once we have these, it'll be a foregone conclusion.
DYOR
Competition???, page-23
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.015(5.77%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 24.5¢ | $265.4K | 1.050M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 130186 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 11571 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |